The investigational atypical antipsychotic ALKS 3831 — combination olanzapine/samidorphan for the treatment of schizophrenia and bipolar I disorder — led to significantly less weight gain than olanzapine (Zyprexa) alone, in the 24-week phase III ENLIGHTEN-2 study. The drug is currently under FDA review with a PDUFA target action date of Nov. 15, 2020. (American Journal of Psychiatry)
In 2015-2016, U.S. adults with depression had triple the odds of daily cannabis use, whereas adults with depression only saw 37% higher odds of near-daily cannabis use a decade prior. (JAMA Network Open)
Especially for the field of mental health, the shift towards telemedicine prompted by the COVID-19 pandemic is likely here to stay. (Social Psychiatry and Psychiatric Epidemiology)
Following Michelle Obama’s revelation that she was suffering from “low-grade depression,” a group of psychiatrists including Altha Stewart, MD, past president of the American Psychiatric Association, penned an open letter to the former first lady. (Chicago Tribune)
Almost 75% of older adults with dementia were prescribed at least one central nervous system-active medication, such as an antidepressant, opioid painkiller, epilepsy drug, anxiety medication, or antipsychotic drug. (JAMA/MedPage Today)
People with ADHD — and more specifically those whose ADHD persisted into adulthood — may be at a higher risk of being involved in a car crash. (ScienceDaily)
“Depression may be intrinsic to early stages of psychotic disorder, and thus treating depression could produce widespread benefit,” researchers reported in a new study appearing in Schizophrenia Bulletin.
Out of 106 modifiable factors spanning lifestyle, social, and environmental variables, confiding in others had the strongest protective effect against depression. (American Journal of Psychiatry)
Source: MedicalNewsToday.com
